Transgene Biotek has informed us that the company has filed two patents for its cancer drug technologies based on its proprietary RNAi platform.
The company has filed its first patent for a liver cancer drug, following excellent results demonstrated in the latest animal studies. It covers a novel technology that employs an AAV vector system genetically modified by Transgene to efficiently express specific microRNA that silence a particular metastasis-promoting gene in liver cancer cells.
Another patent filed by the company is for a breast cancer drug that employs an efficient system, which expresses short interfering RNA cloned in a viral vector that silence a particular metastasis-promoting gene in breast cancer cells. This drug is specifically designed not only to treat primary breast cancer but also to fight against potential metastatic tumours.
The company manufactures both the cancer drugs on its own novel RNAi platform, which has been validated by the results of animal studies, and utilizes a novel gene silencing technology to selectively knock-down specific cancer-producing gene targets.
Transgene is expecting to file more patents on some of its other technologies soon.